Answers are grounded in this paper and cite their sources.
Highlights clinical and radiological markers of pulmonary hypertension in interstitial lung disease, indicating the critical role of computed tomography in diagnosis and treatment selection.
Pulmonary Hypertension (PH) is defined as an increase in the mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, as assessed by the right heart catheterization (RHC), and it may complicate most cardiovascular and respiratory diseases. PH is clinically classified into five groups according to similar clinical presentation, pathological findings, hemodynamic characteristics and treatment strategy. Interstitial Lung Disease (ILD) are listed in Group 3 (due to lung diseases and/or hypoxia) and Group 5 (with unclear and/or multifactorial mechanisms), based on the physio-pathological mechanisms of PH development, with a prevalent precapillary hemodynamic profile. In patients with ILD, the presence of PH is commonly associated with the advanced phase of the disease and an increase in morbidity and mortality. In the context of PH associated with parenchymal lung diseases, the diagnosis is relevant not only for the patients’ prognosis but also for the treatment choice because the use of vasodilator therapy in patients with chronic lung diseases is generally not recommended. Therefore, the role of the radiologist is to look for computed tomography (CT) signs suggestive of PH and to contribute to the identification of the possible cause of PH, becoming familiar with clinical, hemodynamical and physiological aspects of the different diseases.
No takes yet. Share an insight, caveat, or question.
Valentini et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: